The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Digital spatial profiling to uncover biomarkers of immunotherapy outcomes in head and neck squamous cell carcinoma.
 
Niki Gavrielatou
No Relationships to Disclose
 
Ioannis Vathiotis
No Relationships to Disclose
 
Thazin Nwe Aung
No Relationships to Disclose
 
Saba Shafi
No Relationships to Disclose
 
Sneha Burela
No Relationships to Disclose
 
Aileen Fernandez
No Relationships to Disclose
 
Amanda Psyrri
Honoraria - AstraZeneca; Bayer; BMS; Genesis Pharmaceuticals; Merck Serono; MSD Oncology; Pfizer; Rakuten Medical; Roche
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; eTheRNA immunotherapies; MSD Oncology; Pfizer; Rakuten Medical
Research Funding - Amgen; Boehringer Ingelheim; Bristol-Myers Squibb; Demo Pharmaceutical; Kura Oncology; Pfizer; Pharmathen; Roche
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Ipsen; Ipsen; MSD Oncology; Roche
(OPTIONAL) Uncompensated Relationships - AstraZeneca; AstraZeneca
 
David L. Rimm
Stock and Other Ownership Interests - Pixel Gear
Honoraria - Amgen
Consulting or Advisory Role - AstraZeneca; Cell Signaling Technology; Cepheid; Daiichi Sankyo; Danaher; GlaxoSmithKline; Konica Minolta; Merck; NanoString Technologies; NextCure; PAIGE.AI; Regeneron; Roche; Sanofi; Verily
Research Funding - Amgen (Inst); Cepheid (Inst); Konica Minolta (Inst); Navigate Biopharma (Inst); NextCure (Inst)
Patents, Royalties, Other Intellectual Property - Quantitative Immunofluorescence (AQUA) (Inst); Rarecyte Circulating tumor cells
Expert Testimony - Bryan Cave Leighton Paisner